Two major pharmaceutical manufacturers are holding dominant positions due to their early entry into incretin-based obesity therapies and strong clinical validation
Importantly, GLP-1 receptors have been demonstrated in multiple organs throughout the body, including the pancreatic islets, gastrointestinal tract, kidney, lung, heart and centrally within the hypothalamus and pituitary [28]
Connectivity and wearable devices are transforming the way patients manage their health, and we are working on this path of innovation, she says
Moreover, they can compare your circumstances, set the right dose, and cope with troubles
A clinical study of a GLP-1 RA highlighted that participants who followed dietary advice and injected weekly saw an average 18% lower energy intake compared to placebo, with significant reductions in body weight and cardio-metabolic risk
Bogart MH et al